Drug Database
Back to search

Poland· PL-100438319

Symgliptin

A sitagliptin product containing sitagliptinum, registered in Poland by Symphar Sp. z o.o.. The same ATC class is registered in 19 of our 19 countries.

ATC A10BH01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedSymgliptinATCA10BH01REGISTER NO.PL-100438319PACKS LISTED8CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about sitagliptinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Sitagliptin is registered in 19 of 19 countries.

Countries holding a registration under ATC A10BH01 (sitagliptin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 11 of them publish a price we can compare per daily dose
Search sitagliptin products by name

Sitagliptin · ATC A10BH01

19 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of sitagliptin costs, country by country.

Normalised to the WHO defined daily dose (0.1 g), the median price runs from $0.65 in France to $5.47 in Switzerland — a ×8.4 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Sitagliptin · price per daily dose (0.1 g)

USD · FX 28 Sept 2026

  • CH Switzerland$5.47
  • IT Italy$1.78
  • ES Spain$1.08
  • FR France$0.65
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Sitagliptinum
Manufacturer
Symphar Sp. z o.o.
Country
Poland (PL)
ATC code
A10BH01
ATC class
Sitagliptin
Defined daily dose
0.1 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 8

  • gtin
    05905669739191
  • gtin
    05905669739252
  • gtin
    05905669739245
  • gtin
    05905669739207
  • gtin
    05905669739221
  • gtin
    05905669739214
  • gtin
    05905669739238
  • gtin
    05905669739269

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

341 interactions on record for sitagliptin.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check sitagliptin against other medicinesHow interaction checks work

Sitagliptin · interactions on record

341 records

  • 3 severe
  • 292 moderate
  • 44 minor

Most severe, free to view

  • GatifloxacinJ01MA16severe
  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate

2 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under A10BH01

Sitagliptin, as other registers publish it.

All sitagliptin products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b771bf0b-af09-4741-a4e7-26a930b8c118
GET /v1/drugs/b771bf0b-af09-4741-a4e7-26a930b8c118?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "25 mg",
  "packaging": "05905669739191 ¦ Rp ¦ 144273\n14 tabl.\n05905669739252 ¦ Rp ¦ 144274\n90 tabl.\n05905669739245 ¦ Rp ¦ 144275\n84 tabl.\n05905669739207 ¦ Rp ¦ 144276\n28 tabl.\n05905669739221 ¦ Rp ¦ 144277\n50 tabl.\n05905669739214 ¦ Rp ¦ 144278\n30 tabl.\n05905669739238 ¦ Rp ¦ 144279\n56 tabl.\n05905669739269 ¦ Rp ¦ 144280\n98 tabl.",
  "substance": "Sitagliptini hydrochloridum monohydricum 28.344 mg",
  "common_name": "Sitagliptinum",
  "pl_product_id": "100438319",
  "pozwolenie_nr": "26972",
  "auth_procedure": "DCP",
  "authorisation_validity": "2027-03-21"
}
API referenceMCP serverPlans

See everything about sitagliptin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console